The same day congressional voiced aired concern over Marathon’s $89,000 price of a decades-old Duchenne Muscular Disorder treatment, EMFLAZA (deflazacort), Marathon’s CEO released a statement Monday citing that the company is pausing their “commercialization efforts.” Noting a steep price difference between EMFLAZA and its generic, lawmakers were first to criticize the brand which did not develop the drug. Marathon’s statement indicates that it will reinvest any earnings from EMFLASA into continual Duchenne research. Read the full article here.